Citations as recorded by:

1. Adverse effects of imatinib in children with chronic myelogenous leukemia

Pediatrics International, 2017, 59(3) p. 286

DOI: 10.1111/ped.13136

Citations as recorded by: Cross Ref Google

2. Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia

Pediatr Blood Cancer, 2016, 63(8) p. 1332

DOI: 10.1002/pbc.26028

Citations as recorded by: Cross Ref Google

3. Optimal management for pediatric chronic myeloid leukemia

Pediatrics International, 2016, 58(3) p. 171

DOI: 10.1111/ped.12876

Citations as recorded by: Cross Ref Google

4. Changes in the Dickkopf-1 and tartrate-resistant acid phosphatase 5b serum levels in preschool children with nephrotic syndrome

4(5) p. 605

DOI: 10.3892/br.2016.631

Citations as recorded by: Cross Ref PMC Google

5. Off-Target Effects of BCR-ABL and JAK2 Inhibitors

American Journal of Clinical Oncology, 2016, 39(1) p. 76

DOI: 10.1097/COC.0000000000000023

Citations as recorded by: Cross Ref Google

6. Imatinib in the Treatment of Chronic Myeloid Leukemia in Children and Adolescents is Effective and well-tolerated

Year: 2016

Citations as recorded by: Google

7. Adverse skeletal effects of drugs - beyond Glucocorticoids

Clin Endocrinol, 2015, 82(1) p. 12

DOI: 10.1111/cen.12549

Citations as recorded by: Cross Ref

8. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015

Bone Marrow Transplant, 2015, 50(8) p. 1037

DOI: 10.1038/bmt.2015.6

Citations as recorded by: Cross Ref

9. Inhibitory effects of imatinib on vitamin D3 synthesis in human keratinocytes

11(4) p. 3143

DOI: 10.3892/mmr.2014.3074

Citations as recorded by: Cross Ref Google

10. Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats

PLoS ONE, 2015, 10(6) p. e0131192

DOI: 10.1371/journal.pone.0131192

Citations as recorded by: Cross Ref PMC Google

11. Indications for allo-and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015

Year: 2015

Citations as recorded by: Google

12. Adverse skeletal effects of drugs–beyond Glucocorticoids

Year: 2015

Citations as recorded by: Google

13. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase

Pediatr Blood Cancer, 2014, 61(2) p. 355

DOI: 10.1002/pbc.24521

Citations as recorded by: Cross Ref Google

14. Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

Pediatr Blood Cancer, 2014, 61(11) p. 2080

DOI: 10.1002/pbc.25090

Citations as recorded by: Cross Ref Google

15. Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients

Leukemia Research, 2014, 38(5) p. 594

DOI: 10.1016/j.leukres.2014.02.011

Citations as recorded by: Cross Ref Google

16. Managing children with chronic myeloid leukaemia (CML)

Br J Haematol, 2014, 167(1) p. 33

DOI: 10.1111/bjh.12977

Citations as recorded by: Cross Ref Google

17. Managing children with chronic myeloid leukaemia (CML) Recommendations for the management of CML in children and young people up to the age of 18 years

Year: 2014

Citations as recorded by: Google

18. Profile of imatinib in pediatric leukemia

Year: 2014

Citations as recorded by: Google

19. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model

Year: 2013

Citations as recorded by: Google